Advertisement

Advertisement

HK:2105 Stock Latest News

Laekna Grants Vasque Bio Global Rights to LAE118 Outside Greater China

Company AnnouncementsLaekna Grants Vasque Bio Global Rights to LAE118 Outside Greater China

Laekna Shareholders Approve All Resolutions at 2026 AGM

PremiumCompany Announcements

Laekna Shareholders Approve All Resolutions at 2026 AGM

16d ago

Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate

PremiumCompany Announcements

Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate

1M ago

Laekna grants 15.3 million RSUs under 2024 share award scheme

PremiumCompany Announcements

Laekna grants 15.3 million RSUs under 2024 share award scheme

1M ago

Laekna’s Breast Cancer Drug LAE002 Hits Phase III PFS Goal, NDA in China Planned

PremiumCompany Announcements

Laekna’s Breast Cancer Drug LAE002 Hits Phase III PFS Goal, NDA in China Planned

2M ago

Laekna Advances Obesity Candidate LAE102 With Positive Phase I Data

PremiumCompany AnnouncementsLaekna Advances Obesity Candidate LAE102 With Positive Phase I Data

3M ago

Laekna Announces Positive Phase I Results for Obesity-Targeted Antibody LAE102

Company Announcements

Laekna Announces Positive Phase I Results for Obesity-Targeted Antibody LAE102

3M ago

Laekna Sets March 2026 Board Meeting to Approve 2025 Annual Results

Company Announcements

Laekna Sets March 2026 Board Meeting to Approve 2025 Annual Results

4M ago

Laekna Wins FDA Acceptance of IND for New PI3Kα Inhibitor LAE118

PremiumCompany Announcements

Laekna Wins FDA Acceptance of IND for New PI3Kα Inhibitor LAE118

5M ago

Laekna Doses First Subject in Phase I Trial of Metabolic Drug Candidate LAE103

PremiumCompany Announcements

Laekna Doses First Subject in Phase I Trial of Metabolic Drug Candidate LAE103

6M ago

Laekna Doses First Patient in Phase I Multiple-Dose Expansion Study of Obesity Drug LAE102

PremiumCompany Announcements

Laekna Doses First Patient in Phase I Multiple-Dose Expansion Study of Obesity Drug LAE102

6M ago

Laekna Completes Enrollment for Phase III Breast Cancer Trial

PremiumCompany Announcements

Laekna Completes Enrollment for Phase III Breast Cancer Trial

6M ago

Laekna, Inc. Updates Nomination and Governance Committee

PremiumCompany AnnouncementsLaekna, Inc. Updates Nomination and Governance Committee

6M ago

Laekna, Inc. Announces Board of Directors and Committee Roles

Company Announcements

Laekna, Inc. Announces Board of Directors and Committee Roles

6M ago

Laekna, Inc. Updates Governance Committee Terms

Company Announcements

Laekna, Inc. Updates Governance Committee Terms

6M ago

Laekna, Inc. Partners with Qilu Pharma for Exclusive Licensing of LAE002 in China

PremiumCompany Announcements

Laekna, Inc. Partners with Qilu Pharma for Exclusive Licensing of LAE002 in China

7M ago

Laekna, Inc. Advances Breast Cancer Treatment with Promising Clinical Study

PremiumCompany Announcements

Laekna, Inc. Advances Breast Cancer Treatment with Promising Clinical Study

8M ago

Laekna, Inc. Advances Obesity Treatment with LAE102 Study

PremiumCompany Announcements

Laekna, Inc. Advances Obesity Treatment with LAE102 Study

8M ago

Laekna, Inc. Reports Positive Phase I Results for Obesity Treatment

PremiumCompany Announcements

Laekna, Inc. Reports Positive Phase I Results for Obesity Treatment

9M ago

Laekna, Inc. Completes Successful Share Placement to Boost R&D

PremiumCompany AnnouncementsLaekna, Inc. Completes Successful Share Placement to Boost R&D

9M ago

Laekna, Inc. Advances Obesity Treatment with Promising Clinical Trial Results

Company Announcements

Laekna, Inc. Advances Obesity Treatment with Promising Clinical Trial Results

10M ago

Laekna, Inc. Secures FDA Approval for New Metabolic Disease Therapy

Company Announcements

Laekna, Inc. Secures FDA Approval for New Metabolic Disease Therapy

11M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >